



### Supplementary Fig. S4. The pharmacokinetic (PK) parameters and anti-tumor efficacy of BEBT-908

(A) The antitumor activity of Ctrl., GDC-0941, SAHA alone or a combination at maximum tolerated doses (MTD) of each treatment, orally 5 times weekly in Daudi xenograft SCID mice. The treatments started when tumor size was around 150 mm<sup>3</sup>. Data present mean  $\pm$  SEM, n=8, p values were determined by two-way ANOVA, ns, no significance; \*\*\*\*, p<0.0001.

(B) The pharmacokinetic (PK) parameters in plasma and in tumor tissues of BEBT-908 treated Daudi xenografts.  $t_{1/2}$  means the clearance half-life of BEBT-908.  $T_{max}$  means the time of maximum concentration observed of BEBT-908.  $C_{max}$  means the maximum concentration observed of BEBT-908.  $AUC_{0-24}$  means the area under the concentration time curve (0-24h).

(C-E) Body weight changes of H2122 (C), HCT116 (D), MC38 (E) tumor bearing mice treated with BEBT-908 in Figure 4A-C. n=8 mice per group. Data represent mean  $\pm$  SEM.

(F-G) MDA content in tumor tissues from Ctrl. and BEBT-908 treated HCT116 tumors (F, n=5 tumors per group) and MC38 tumors (G, n=4 tumors per group) at the end of animal experiments. Data present mean  $\pm$  SEM. p values were determined by unpaired two-sided t test. \*, p<0.05.